Merit Medical Systems Free Cash Flow 2010-2024 | MMSI
Merit Medical Systems free cash flow from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Merit Medical Systems Annual Free Cash Flow |
2023 |
111.06 |
2022 |
69.33 |
2021 |
120.33 |
2020 |
119.32 |
2019 |
0.56 |
2018 |
23.26 |
2017 |
24.13 |
2016 |
20.78 |
2015 |
19.75 |
2014 |
19.24 |
2013 |
-8.02 |
2012 |
-17.66 |
2011 |
-25.18 |
2010 |
11.13 |
2009 |
11.62 |
Merit Medical Systems Quarterly Free Cash Flow |
2024-03-31 |
24.53 |
2023-12-31 |
111.06 |
2023-09-30 |
55.93 |
2023-06-30 |
13.48 |
2023-03-31 |
1.96 |
2022-12-31 |
69.33 |
2022-09-30 |
53.81 |
2022-06-30 |
34.09 |
2022-03-31 |
2.48 |
2021-12-31 |
120.33 |
2021-09-30 |
82.84 |
2021-06-30 |
64.51 |
2021-03-31 |
29.93 |
2020-12-31 |
119.32 |
2020-09-30 |
92.80 |
2020-06-30 |
47.44 |
2020-03-31 |
14.91 |
2019-12-31 |
0.56 |
2019-09-30 |
-6.94 |
2019-06-30 |
-0.25 |
2019-03-31 |
-4.75 |
2018-12-31 |
23.26 |
2018-09-30 |
15.84 |
2018-06-30 |
3.49 |
2018-03-31 |
-8.30 |
2017-12-31 |
24.13 |
2017-09-30 |
13.88 |
2017-06-30 |
16.79 |
2017-03-31 |
5.00 |
2016-12-31 |
20.78 |
2016-09-30 |
9.85 |
2016-06-30 |
4.22 |
2016-03-31 |
0.59 |
2015-12-31 |
19.75 |
2015-09-30 |
17.55 |
2015-06-30 |
15.02 |
2015-03-31 |
9.78 |
2014-12-31 |
19.24 |
2014-09-30 |
7.39 |
2014-06-30 |
1.44 |
2014-03-31 |
-0.73 |
2013-12-31 |
-8.02 |
2013-09-30 |
-14.34 |
2013-06-30 |
-15.97 |
2013-03-31 |
-17.06 |
2012-12-31 |
-17.66 |
2012-09-30 |
-17.09 |
2012-06-30 |
-13.18 |
2012-03-31 |
-10.25 |
2011-12-31 |
-25.18 |
2011-09-30 |
-8.37 |
2011-06-30 |
-8.04 |
2011-03-31 |
-3.94 |
2010-12-31 |
11.13 |
2010-09-30 |
5.05 |
2010-06-30 |
6.11 |
2010-03-31 |
0.76 |
2009-12-31 |
11.62 |
2009-09-30 |
8.47 |
2009-06-30 |
8.83 |
2009-03-31 |
6.03 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical & Dental Supplies |
$4.758B |
$1.257B |
Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company offers products focused in five core product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, cardiovascular and critical care as well as endoscopy. However, the company operates in two revenue segments: Cardiovascular and Endoscopy Devices.
|